Table 1 Patient Characteristics stratified based on the site of relapse—CNS only relapse versus CNS and systemic relapse prior to CAR-T
Variable | All patients N = 61 (%) | CNS only relapse N = 20 (%) | CNS and systemic relapse N = 41 (%) | p-value |
|---|---|---|---|---|
Patient related | ||||
Age at diagnosis | 0.79 | |||
Median, range (yrs) | 56 (18–82) | 56 (31–82) | 56 (18–73) | |
> 60 yrs | 17 (18) | 6 (30) | 11 (27) | |
≤ 60 yrs | 44 (72) | 14 (70) | 30 (73) | |
Sex, n (%) | 0.31 | |||
Males | 34 (56) | 13 (65) | 21 (51) | |
Females | 27 (44) | 7 (35) | 20 (49) | |
COPD | 1.00 | |||
Yes | 3 (5) | 1 (5) | 2 (5) | |
No | 58 (95) | 19 (95) | 39 (95) | |
Cardiac co-morbidities* | 0.73 | |||
Yes | 12 (20) | 3 (15) | 9 (22) | |
No | 49 (80) | 17 (85) | 32 (78) | |
Disease related | ||||
Histologic subtype | 0.22 | |||
De novo DLBCL | 50 (82) | 16 (80) | 34 (83) | |
tFL | 5 (8) | 1 (5) | 4 (10) | |
tMZL | 2 (3) | 2 (10) | 0 (0) | |
Others** | 4 (7) | 1 (5) | 3 (7) | |
DHL | 16 (30) | 0 (0) | 16 (43) | 0.003 |
IPI at diagnosis | 0.67 | |||
0 | 1 (2) | 0 (0) | 1 (3) | |
1–2 | 15 (29) | 6 (37) | 9 (26) | |
≥ 3 | 35 (69) | 10 (63) | 25 (71) | |
Primary refractory disease^ | 0.34 | |||
Yes | 15 (25) | 3 (15) | 12 (30) | |
No | 45 (75) | 17 (85) | 28 (70) | |
CAR-T related | ||||
Lines of therapy prior to CART | 0.21 | |||
Median, range | 3 (1–5) | 3 (2–5) | 3 (1–5) | |
≤ 2 | 21 (36) | 9 (45) | 12 (31) | |
3 | 27 (46) | 6 (30) | 21 (54) | |
≥ 4 | 11 (19) | 5 (25) | 6 (15) | |
Prior HD-MTX containing salvage regimen | 0.52 | |||
Yes | 24 (41) | 7 (35) | 17 (44) | |
No | 35 (59) | 13 (65) | 22 (56) | |
Prior auto-HCT | 0.03 | |||
Yes | 14 (23) | 8 (40) | 6 (15) | |
No | 47 (77) | 12 (60) | 35 (85) | |
Median time from diagnosis to CAR-T, range (months) | 15.8 (3.1–257.4) | 23.1 (3.6–101.1) | 13.3 (3.1–257.4) | 0.04 |
CAR-T product | 0.54 | |||
Axi-cel | 30 (49) | 9 (45) | 21 (51) | |
Tisa-cel | 19 (31) | 7 (35) | 12 (29) | |
Liso-cel | 11 (18) | 3 (15) | 8 (20) | |
Brexu-cel | 1 (2) | 1 (5) | 0 | |
Median age at apheresis, range (yrs) | 58 (18–83) | 59 (53–83) | 58 (46–74) | 0.39 |
ECOG PS at apheresis | 0.02 | |||
0–1 | 47 (77) | 19 (95) | 28 (68) | |
≥ 2 | 14 (23) | 1 (5) | 13 (32) | |
Median serum creatinine at apheresis, range | 0.87 (0.40–1.67) | 0.85 (0.49–1.67) | 0.87 (0.40–1.20) | 0.92 |
Site of CNS involvement | 0.04 | |||
Parenchymal | 25 (42) | 13 (65) | 12 (30) | |
Leptomeningeal | 29 (48) | 6 (30) | 23 (58) | |
Both | 6 (10) | 1 (5) | 5 (12) | |
Best response to last line of therapy prior to CAR-T | < 0.001 | |||
CR | 3 (5) | 2 (10) | 1 (2) | |
PR | 19 (31) | 10 (50) | 9 (22) | |
Chemorefractory | 39 (64) | 8 (40) | 31 (76) | |
Bridging | 0.56 | |||
Chemo only | 23 (38) | 8 (40) | 15 (37) | |
Chemo + XRT | 5 (8) | 2 (10 | 3 (7) | |
XRT only | 9 (15) | 1 (5) | 8 (19) | |
None | 24 (39) | 9 (45) | 15 (37) | |
Best response to CAR-T among evaluable patients (n = 56) | 1.00 | |||
CR | 32 (57) | 11 (61) | 21 (55) | |
PR | 6 (11) | 2 (11) | 4 (11) | |
SD | 4 (7) | 1 (6) | 3 (8) | |
PD | 14 (25) | 4 (22) | 10 (26) | |